PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF Russian patent published in 2020 - IPC C07D471/14 C07D487/14 A61K31/519 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to 5-aryl-pyrimidoindolizine or 5-aryl-pyrimidopyrrolizine compound of formula I, in which R₁ denotes H, methyl or methylidene; L is -O-, -C(=O) NH- or -C(=O)NHCHR₂-, where R₂ is substituted C₁-C₃ alkyl and the substitute in R₂ is C₁-C₃ alkoxy; m is 0 or 1; Ar represents substituted or unsubstituted C₆ aryl, substituted or unsubstituted 6-membered heteroaryl containing one heteroatom N, wherein the substituent in Ar represents halogen or trifluoromethyl, A is carbonyl, sulfonyl or where R₃ and R₄ independently represent hydrogen or C₁-C₃ alkyl, or R₃, R₄ together with a carbon atom attached thereto form C₃-C₅ cycloalkyl; n is equal to 1; T is or ; R₅, R₆ and R₇ are independently selected from a group consisting of hydrogen, cyano and substituted or unsubstituted C₁-C₅ alkyl; the substitute in R₅, R₆ or R₇ is dimethylamino; R₈ is methyl. Invention also relates to a method of producing, to a pharmaceutical composition and to use of 5-aryl-pyrimidoindolizine or 5-aryl-pyrimidopyrroline compound for preparing a drug for treating human lymphoma related to signal transduction of BTK kinase.

EFFECT: technical result: obtaining novel 5-aryl-pyrimidoindolizine and 5-aryl-pyrimidopyrrolizine compounds of formula I, having inhibitory activity on BTK.

8 cl, 24 ex